Living reference work entry


Prostatic acid phosphatase (PAP) is a 100 kDa glycoprotein synthesized by well-differentiated prostatic gland columnar epithelia and secreted in large quantity in seminal fluid (Hassan et al. 2010). PAP is present in elevated concentrations in the serum of men who have prostate cancer or other prostatic diseases (Hassan et al. 2010). The PAP gene is located along the long arm of chromosome 3 at locus 21 (3q21), and the protein product exists as intracellular, transmembrane, and secreted forms, with slightly different biochemical properties differentiating each of these (Hassan et al. 2010; Solin et al. 1990).


Antigen-presenting cells (APCs) Castration-resistant prostate cancer (CRPC) Cytotoxic T-lymphocyte (CTL) activity Prostate cancer Prostatic acid phosphatase (PAP) Assessment Biology Clinical data Clinical utility of CRPC CTL activity Immunological strategies Multivariate analysis Preoperative levels Prognostic value Therapeutics Radioimmunoassay (RAI) 


  1. Becker JT, Olson BM, Johnson LE, et al. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother. 2010;33(6):639–47.CrossRefPubMedPubMedCentralGoogle Scholar
  2. Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res. 2000;6:2175–82.PubMedGoogle Scholar
  3. Dattoli M, Wallner K, True L, et al. Long-term prostate cancer control using Palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension. Urology. 2007;69:334–7.CrossRefPubMedGoogle Scholar
  4. Fong L, Ruegg CL, Brockstedt D, et al. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization; implications for immunotherapy of prostate cancer. J Immunol. 1997;159:3113–7.PubMedGoogle Scholar
  5. Han M, Piantadosi S, Zahurak ML, et al. Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. Urology. 2001;57:707–11.CrossRefPubMedGoogle Scholar
  6. Hassan M, Aijaz A, Ahmad F. Structural and functional analysis of human prostatic acid phosphatase. Expert Rev Anticancer Ther. 2010;10(7):1055–68.CrossRefPubMedGoogle Scholar
  7. Johnson DE, Prout GR, Scott WW, et al. Clinical significance of serum acid phosphatase levels in advanced prostatic carcinoma. Urology. 1976;8:123–6.CrossRefPubMedGoogle Scholar
  8. Johnson LE, Frye TP, Arnot AR, et al. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine. 2006;24:293–303.CrossRefPubMedGoogle Scholar
  9. Johnson LE, Frye TP, Chinnasamy N, et al. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. Cancer Immunol Immunother. 2007;56:885–95.CrossRefPubMedGoogle Scholar
  10. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucell-T immunotherapy for castration-resistant prostate cancer. NEJM. 2010;363(5):411–22.CrossRefPubMedGoogle Scholar
  11. Lin MF, Lee MS, Zhou XW, et al. Decreased expression of cellular prostatic acid phosphatase increases tumorigenicity of human prostate cancer cells. J Urol. 2001;166:1943–50.CrossRefPubMedGoogle Scholar
  12. McNeel DG, Dunphy EJ, Davies JG, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. JCO. 2009;27(25):4047–54.CrossRefGoogle Scholar
  13. Meng TC, Lee MS, Lin MF. Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells. Oncogene. 2000;19(22):2664–77.CrossRefPubMedGoogle Scholar
  14. Moul JW, Connelly RR, Perahia B, et al. The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. J Urol. 1998;159:935–40.CrossRefPubMedGoogle Scholar
  15. Quintero IB, Araujo CL, Pulkka AE, et al. Prostatic acid phosphatase is not a prostate specific target. Cancer Res. 2007;67(14):6549–54.CrossRefPubMedGoogle Scholar
  16. Reif AE, Schlesinger RM, Fish CA, et al. Acid phosphatase isozymes in cancer of the prostate. Cancer. 1973;31:689–99.CrossRefPubMedGoogle Scholar
  17. Romas NA. Prostatic acid phosphatase: current concepts. Semin Urol. 1983;1:177–85.PubMedGoogle Scholar
  18. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. JCO. 2000;18(23):3894–903.Google Scholar
  19. Solin T, Kontturi M, Pohlmann R, et al. Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): evaluation by RNA blot analysis. Biochem Biophys Acta. 1990;1048(1):72–7.PubMedGoogle Scholar
  20. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909–16.CrossRefPubMedGoogle Scholar
  21. Taira A, Merrick G, Wallner K, et al. Reviving the acid phosphatase test for prostate cancer. Oncology. 2007;21(8):1003–10.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Medical Oncology BranchNational Cancer InstituteBethesdaUSA

Personalised recommendations